Reply to Hassoun et al

Hassoun and colleagues question whether the hospital-acquired (HAP) and ventilator-associated pneumonia (VAP) guidelines recently published in Clinical Infectious Diseases were "fair and balanced" in their review of telavancin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) pneumonia [1, 2].

http://ift.tt/2qvkwvo